146 related articles for article (PubMed ID: 36310058)
61. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
62. Polycomb protein Ezh1 promotes RNA polymerase II elongation.
Mousavi K; Zare H; Wang AH; Sartorelli V
Mol Cell; 2012 Jan; 45(2):255-62. PubMed ID: 22196887
[TBL] [Abstract][Full Text] [Related]
63. Reaction coupling between wild-type and disease-associated mutant EZH2.
Swalm BM; Knutson SK; Warholic NM; Jin L; Kuntz KW; Keilhack H; Smith JJ; Pollock RM; Moyer MP; Scott MP; Copeland RA; Wigle TJ
ACS Chem Biol; 2014 Nov; 9(11):2459-64. PubMed ID: 25154026
[TBL] [Abstract][Full Text] [Related]
64. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
[TBL] [Abstract][Full Text] [Related]
65. Inhibitors of the Histone Methyltransferases EZH2/1 Induce a Potent Antiviral State and Suppress Infection by Diverse Viral Pathogens.
Arbuckle JH; Gardina PJ; Gordon DN; Hickman HD; Yewdell JW; Pierson TC; Myers TG; Kristie TM
mBio; 2017 Aug; 8(4):. PubMed ID: 28811345
[TBL] [Abstract][Full Text] [Related]
66. Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.
Xia J; Li J; Tian L; Ren X; Liu C; Liang C
J Med Chem; 2022 May; 65(10):7016-7043. PubMed ID: 35531606
[TBL] [Abstract][Full Text] [Related]
67. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
68. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
[TBL] [Abstract][Full Text] [Related]
69. EZH1 is an antipsychotic-sensitive epigenetic modulator of social and motivational behavior that is dysregulated in schizophrenia.
Johnstone AL; O'Reilly JJ; Patel AJ; Guo Z; Andrade NS; Magistri M; Nathanson L; Esanov R; Miller BH; Turecki G; Brothers SP; Zeier Z; Wahlestedt C
Neurobiol Dis; 2018 Nov; 119():149-158. PubMed ID: 30099093
[TBL] [Abstract][Full Text] [Related]
70. Ezh1 Targets Bivalent Genes to Maintain Self-Renewing Stem Cells in Ezh2-Insufficient Myelodysplastic Syndrome.
Aoyama K; Oshima M; Koide S; Suzuki E; Mochizuki-Kashio M; Kato Y; Tara S; Shinoda D; Hiura N; Nakajima-Takagi Y; Sashida G; Iwama A
iScience; 2018 Nov; 9():161-174. PubMed ID: 30396150
[TBL] [Abstract][Full Text] [Related]
71. EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys
Huang JP; Ling K
Oncol Lett; 2017 Nov; 14(5):5735-5742. PubMed ID: 29113202
[TBL] [Abstract][Full Text] [Related]
72. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.
Kim W; Bird GH; Neff T; Guo G; Kerenyi MA; Walensky LD; Orkin SH
Nat Chem Biol; 2013 Oct; 9(10):643-50. PubMed ID: 23974116
[TBL] [Abstract][Full Text] [Related]
73. EZ Switch From EZH2 to EZH1: Histone Methylation Opens a Window of Cardiac Regeneration.
Kook H; Seo SB; Jain R
Circ Res; 2017 Jul; 121(2):91-94. PubMed ID: 28684617
[No Abstract] [Full Text] [Related]
74. EZH1 and EZH2 promote skeletal growth by repressing inhibitors of chondrocyte proliferation and hypertrophy.
Lui JC; Garrison P; Nguyen Q; Ad M; Keembiyehetty C; Chen W; Jee YH; Landman E; Nilsson O; Barnes KM; Baron J
Nat Commun; 2016 Nov; 7():13685. PubMed ID: 27897169
[TBL] [Abstract][Full Text] [Related]
75. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
Dockerill M; Gregson C; O' Donovan DH
Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
[TBL] [Abstract][Full Text] [Related]
76. [Development of future treatment for ATL].
Ishitsuka K
Rinsho Ketsueki; 2021; 62(7):766-773. PubMed ID: 34349061
[TBL] [Abstract][Full Text] [Related]
77. Polycomb repressive complex 2 regulates normal development of the mouse heart.
He A; Ma Q; Cao J; von Gise A; Zhou P; Xie H; Zhang B; Hsing M; Christodoulou DC; Cahan P; Daley GQ; Kong SW; Orkin SH; Seidman CE; Seidman JG; Pu WT
Circ Res; 2012 Feb; 110(3):406-15. PubMed ID: 22158708
[TBL] [Abstract][Full Text] [Related]
78. Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells.
Mochizuki-Kashio M; Mishima Y; Miyagi S; Negishi M; Saraya A; Konuma T; Shinga J; Koseki H; Iwama A
Blood; 2011 Dec; 118(25):6553-61. PubMed ID: 22042701
[TBL] [Abstract][Full Text] [Related]
79. Chromatin regulated interchange between polycomb repressive complex 2 (PRC2)-Ezh2 and PRC2-Ezh1 complexes controls myogenin activation in skeletal muscle cells.
Stojic L; Jasencakova Z; Prezioso C; Stützer A; Bodega B; Pasini D; Klingberg R; Mozzetta C; Margueron R; Puri PL; Schwarzer D; Helin K; Fischle W; Orlando V
Epigenetics Chromatin; 2011 Sep; 4():16. PubMed ID: 21892963
[TBL] [Abstract][Full Text] [Related]
80. Phosphorylation of EZH2 by CDK1 and CDK2: a possible regulatory mechanism of transmission of the H3K27me3 epigenetic mark through cell divisions.
Zeng X; Chen S; Huang H
Cell Cycle; 2011 Feb; 10(4):579-83. PubMed ID: 21278485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
